SCHEMBL12469388

SCHEMBL12469388

Cc1sc(-c2ccccc2O)nc1CO

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2B P41595 6/20 0.57
TRPM8 Q7Z2W7 3/20 0.44
ALDH1A1 P00352 5/20 0.40
KDM4E B2RXH2 3/20 0.40
CDC7 O00311 1/20 0.39
DBF4 Q9UBU7 1/20 0.39
ILK Q13418 1/20 0.39
MAPT P10636 2/20 0.39
NPC1 O15118 2/20 0.39
RAB9A P51151 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
HPGD P15428 2/20 0.38
HSD17B10 Q99714 2/20 0.38
LMNA P02545 1/20 0.38
ALOX15 P16050 1/20 0.38
TSHR P16473 1/20 0.38
NPY1R P25929 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15423021 0.80 HTR2B (0.64) HTR2BTRPM8ALDH1A1ILKMAPT
SCHEMBL24919879 0.80 HTR2B (0.64) HTR2BTRPM8
SCHEMBL4034919 0.78 RARA (0.49) TRPM8ALDH1A1CDC7DBF4MAPT
SCHEMBL23624312 0.77 KDM4E (0.35) HTR2BALDH1A1KDM4EMAPTNPC1
SCHEMBL9313715 0.75 HTR2B (0.53) HTR2BTRPM8ALDH1A1KDM4EILK
Pulicatin D SCHEMBL15411346 0.73 HTR2B (1.00) HTR2BTRPM8ALDH1A1KDM4ECDC7
Alcohol SCHEMBL28246552 0.73 KDM4E (0.63) ALDH1A1KDM4EILKMAPTNPC1
SCHEMBL259573 0.72 HTR2B (0.48) HTR2BTRPM8MAPTHSD17B10LMNA
SCHEMBL15423062 0.72 HTR2B (0.55) HTR2BTRPM8ALDH1A1KDM4EMAPT
SCHEMBL12469453 0.72 HTR2B (0.58) HTR2BTRPM8ALDH1A1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11421223-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2022-08-23 US disclosed
US-20190309289-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2019-10-10 US disclosed
US-10370654-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. (US) 2019-08-06 US disclosed
US-20180320170-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2018-11-08 US disclosed
US-9944925-B2 Processes and host cells for genome, pathway, and biomolecular engineering ENEVOLV, INC. 2018-04-17 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-9751847-B2 Methods and compositions related to neuroactive thiazoline compounds UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2017-09-05 US disclosed
US-20160186168-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. 2016-06-30 US disclosed
EP-3027754-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING enEvolv, Inc. (US) 2016-06-08 EP disclosed
WO-2015017866-A1 PROCESSES AND HOST CELLS FOR GENOME, PATHWAY, AND BIOMOLECULAR ENGINEERING ENEVOLV, INC. (US) 2015-02-05 WO disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2014-01-16 US disclosed
WO-2012051502-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) 2012-04-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018400-A1 METHODS AND COMPOSITIONS RELATED TO NEUROACTIVE THIAZOLINE COMPOUNDS TACR2, TACR3, TACR1 HTR2B 58/4885TRPM8 161/4885ALDH1A1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.